Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.45 |
| ▸ | PGR | P06401 | 4/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21021670 | 0.89 | ACHE (0.50) | ERN1SYKHTTSMN1; SMN2FFAR4 | |
| SCHEMBL13422804 | 0.85 | FFAR4 (0.49) | SYKHTTSMN1; SMN2FFAR4ACHE | |
| SCHEMBL14446041 | 0.84 | ACHE (0.58) | SYKSMN1; SMN2ACHEBACE1 | |
| SCHEMBL18593397 | 0.84 | ERN1 (0.56) | ERN1SYKSMN1; SMN2FFAR4NR3C1 | |
| SCHEMBL15997561 | 0.84 | FFAR4 (0.49) | ERN1SYKFFAR4NR3C1PGR | |
| SCHEMBL6608193 | 0.83 | SYK (0.52) | ERN1SYKSMN1; SMN2FFAR4NR3C1 | |
| SCHEMBL8940603 | 0.82 | ERN1 (0.51) | ERN1SMN1; SMN2NR3C1PGR | |
| SCHEMBL5326539 | 0.80 | ERN1 (0.52) | ERN1SYKSMN1; SMN2FFAR4NR3C1 | |
| SCHEMBL24476966 | 0.80 | KDM1A (0.53) | ERN1SYKFFAR4NR3C1PGR | |
| SCHEMBL2002821 | 0.80 | ERN1 (0.59) | ERN1SYKFFAR4NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012065958-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| WO-2010136474-A2 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | MME, AGTR1, REN | ERN1 1202/4885SYK 4569/4885HTT 1478/4885 |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | ERN1 1068/4885SYK 4512/4885HTT 3614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.